Bioinformatics Profiling of Missense Mutations

The ability to distinguish missense nucleotide substitutions that contribute to harmful effect from those that do not is a difficult problem usually accomplished through functional in vivo analyses. In this study, instead current biochemical methods, the effects of missense mutations upon protein structure and function were assayed by means of computational methods and information from the databases. For this order, the effects of new missense mutations in exon 5 of PTEN gene upon protein structure and function were examined. The gene coding for PTEN was identified and localized on chromosome region 10q23.3 as the tumor suppressor gene. The utilization of these methods were shown that c.319G>A and c.341T>G missense mutations that were recognized in patients with breast cancer and Cowden disease, could be pathogenic. This method could be use for analysis of missense mutation in others genes.




References:
[1] Graf W.D et al (2000) Can Bioinformatics Help Trace the Steps from
Gene Mutation to Disease? Neurology 55(3):331-3.
[2] Sunyaev S et al (2001) Prediction of deleterious human alleles. Hum
Mol Genet 10(6):591-7.
[3] Steck PA et al (1997) Identification of a candidate tumour suppressor
gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple
advanced cancers. Nat Genet 15:356-362.
[4] Li J et al (1997) Pten, a putative protein tyrosine phosphatase gene
mutated in human brain, breast, and prostate cancer. Science 275:1943-
1947.
[5] Nassiri I et al (2008) Mutational analysis in the MMAC1 gene
associated in patients with Juvenile Polyposis syndrome and Cowden
Disease. AAJC 7(3):25-30.
[6] Otto L et al (1997) Germline mutations in Pten are present in Bannayan-
Zonana Syndrome. Nat Genet 16:333-334.
[7] Stiles B et al (2004) PTENless means more. Dev.Biol 273:175 -184.
[8] Lee J et al (1999) Crystal structure of the PTEN tumor suppressor:
implications for its phosphoinositide phosphatase activity and membrane
association. Cell 99:323-334.
[9] Raftopoulou M et al (2004) Regulation of cell migration by the C2
domain of the tumor suppressor PTEN. Science 303:1179-1181.
[10] http://egp.gs.washington.edu/
[11] http://www.sanger.ac.uk/cosmic/
[12] Bairoch A et al (2005) The Universal Protein Resource (UniProt).
Nucleic Acids Res 33:154-9.
[13] Bao L et al (2005) Prediction of the phenotypic effects of nonsynonymous
single nucleotide polymorphisms using structural and
evolutionary information. Bioinformatics 21:2185-90.
[14] Bardelli A et al (2005) Mutational analysis of gene families in human
cancer. Curr Opin Genet Dev 15:5-12.
[15] Altschul SF et al (1990) Basic local alignment search tool. J Mol Biol
215:403-410.
[16] Nassiri I et al (2008) Pharmacogenomic profiling of the PI3K/PTEN
pathway in sporadic breast cancer. Iranian journal of Biomedical
13(4):209-214.
[17] http://bioinformatics.org/seqext/index.html
[18] Chow L and Baker S (2006) PTEN function in normal and neoplastic
growth. Can Let 241:184-196.
[19] Han S et al (2000) Functional Evaluation of PTEN Missense Mutations
Using in Vitro Phosphoinositide Phosphatase Assay. Can Res 60:3147-
3151.
[20] Henikoff S et al (2003) SIFT: predicting amino acid changes that affect
protein function. Nucleic Acids Res 31:3812-4
[21] Karchin R et al (2005) LS-SNP: large-scale annotation of coding nonsynonymous
SNPs based on multiple information sources.
Bioinformatics 21:2814-20.
[22] Barenboim M et al (2005) Statistical geometry approach to the study of
functional effects of human nonsynonymous SNPs. Hum Mutat 26:471-
6.
[23] Yue P et al (2006) Identification and analysis of deleterious human
SNPs. J Mol Biol 356:1263-74.